<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161457">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912495</url>
  </required_header>
  <id_info>
    <org_study_id>NL44825.078.13</org_study_id>
    <nct_id>NCT01912495</nct_id>
  </id_info>
  <brief_title>Dutch Acute HCV in HIV Study (DAHHS)</brief_title>
  <acronym>DAHHS</acronym>
  <official_title>Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slotervaart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMCN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective open label proof of concept feasibility interventional clinical trial in which
      60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in
      addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds
      at week 4.

      The primary hypothesis of this study is that the subset of patients with a Rapid Viral
      Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and
      ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Viral Responds(SVR) at 24 weeks of follow up after the end of all therapy for the Rapid Viral Response at week 4(RVR4) population.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR 24 weeks after the end of all therapy in the entire study population (with or without RVR4).</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 12 weeks after end of therapy in RVR4 population.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 24 weeks after end of therapy in patients with already a RVR at week 1.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 24 weeks after end of therapy in patients that started therapy ≤12weeks after the presumed HCV infection date versus those after 12 weeks.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations of biomarkers by therapy induced viral eradication: Viral sequencing, mutation analysis, gene expression analysis, and RNA analysis.</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Treatment related (serious) adverse events ((S)AE) and treatment discontinuation for (S)AE.</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Boceprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <arm_group_label>Boceprevir</arm_group_label>
    <other_name>Victrelis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented recent HCV genotype 1 infection (≤26 weeks old at the time of the baseline
             visit) according to definition mentioned below.

          2. Plan to start a Standard Of Care therapy for acute HCV consisting of 24 weeks of
             Peginterferon + Ribavirin. HCV RNA plasma viral load at screening &gt;1000 IU/ml.

          3. A previously performed HCV RNA plasma measurement can be used for screening if &lt;4
             weeks old.

          4. On HAART at the time of screening.

          5. Minimum age 18 years.

        Exclusion Criteria:

          1. Disallowed co-medication that cannot be stopped or replaced: Several potentially
             life-threatening drug-drug interactions (DDI) are possible when boceprevir is
             combined with other drugs. Therefore ALL co-medication, including over-the-counter
             drugs should be checked for potential DDI with DDI table in the Dutch summary of
             product characteristics (SPC, appendix A). If the co-medication is not mentioned in
             the SPC DDI table, www.HCV-druginteractions.org should be used.

          2. Contraindications for the use of full dose of peginterferon alpha-2b or ribavirin:
             neutrophils &lt;0,75×109/l or thrombocytes &lt; 100.000×109/l or a Hb &lt;6.2mmol/L,
             creatinine clearance &lt;50ml/min).

          3. History of liver cirrhosis or &gt;F1 fibrosis on fibroscan. Inclusion of patients with a
             chronic well-controlled HBV (HBV-DNA below the limit of detection) with tenofovir,
             lamivudine or emtricitabine therapy is allowed if fibroscan excludes &gt;F1 fibrosis.
             Fibroscan reports &lt;2 years old can be used for screening. Fibroscan is not required
             for other patients at screening.

          4. HAART was started &lt;4 weeks before baseline visit.

          5. Inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse
             transcriptase inhibitors + Raltegravir (Isentress®) 400mg BID or rilpivirine 25mg QD
             or atazanavir (Reyataz®) 300mg QD + ritonavir (Norvir®) 100mg QD.

          6. Patient that virologically failed HAART in the past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Rijnders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bas Hullegie, MD</last_name>
    <phone>+31613088212</phone>
    <email>b.hullegie@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bart Rijnders, MD, PhD</last_name>
    <phone>+31107033510</phone>
    <email>b.rijnders@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Claassen, MD, PhD</last_name>
      <email>m.claassen@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Bart Rijnders, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Claassen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bas Hullegie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Van den Berk</last_name>
      <phone>0031 205993501</phone>
      <email>G.E.L.vandenBerk@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>Guido Van den Berk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan van der Meer</last_name>
      <phone>0031 205669111</phone>
      <email>j.t.vandermeer@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Jan van den Meer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slotervaart</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Lauw</last_name>
      <email>Fanny.lauw@slz.nl</email>
    </contact>
    <investigator>
      <last_name>Fanny lauw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Richter</last_name>
      <email>crichter@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Bierman</last_name>
      <email>w.f.w.bierman@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Sander van Assen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dirk posthouwer</last_name>
      <email>d.posthouwer@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>dirk posthouwer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMCN</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Koopmans</last_name>
      <phone>0031243616498</phone>
      <email>p.koopmans@aig.umcn.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joop Arends</last_name>
      <phone>0031 88 7555555</phone>
      <phone_ext>1180</phone_ext>
      <email>j.e.arends@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Joop Arends</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Bart Rijnders</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
